Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS

Neurology

Volumn 51, Issue 1, 1998, Pages 289-292

  Calabresi, Peter A ^e   Fields, N S ^g   Maloni, H W ^g   Hanham, A ^d   Carlino, J ^d   Moore, J ^d   Levin, M C ^g   Dhib Jalbut, S ^c   Tranquill, L R ^g   Austin, H ^a   McFarland, Henry F ^f   Racke, M K ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^d Celtrix Pharmaceuticals   (United States)

^e RHODE ISLAND HOSPITAL   (United States)

^f NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT TRANSFORMING GROWTH FACTOR BETA2;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISABILITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTIPLE SCLEROSIS; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0031866885     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.51.1.289     Document Type: Article

References (10)

1. Wahl SM. Transforming growth factor β: the good, the bad, and the ugly. J Exp Med 1994;180:1587-1590.
2. Racke MK, Sriram S, Carlino J, et al. Long-term treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β2. J Neuroimmunol 1993;46:175-183.
3. Beck J, Rondot P, Catinot L, et al. TGF beta-like activity produced during progression of exacerbations in multiple sclerosis. Acta Neurol Scand 1991;84:454-455.
4. Rieckmann P, Albrecht M, Kitze B, et al. Tumor necrosis factor-α mRNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995;37:82-88.
5. Terrell TG, Working PK, Chow CP, Green JD. Pathology of recombinant human transforming growth factor-β1 in rats and rabbits. Int Rev Exp Pathol 1993;34B:43-67.
6. Ketteler M, Noble NA, Border WA. Transforming growth factor-β and angiotensin II: the missing link from glomerular hyperfiltration to glomerulosclerosis? Annu Rev Physiol 1995; 57:279-295.
7. Stone LA, Frank JA, Albert PS, Bash CN, Maloni H, McFarland HF. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995;37:611-619.
8. Choyke PL, Frank JA, Austin HA, et al. Hydrated clearance of gadolinium DTPA as a measurement of glomerular filtration rate. Kidney Int 1992;41:1595-1598.
9. Sanderson N, Factor V, Nagy P, et al. Hepatic expression of mature transforming growth factor β1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA 1995; 92:2572-2576.
10. Fabry Z, Topham DJ, Fee D, et al. TGF-β2 decreases migration of lymphocytes in vitro and homing of cells into the central nervous system in vivo. J Immunol 1995;155:325-332.